Coherus Oncology, Inc. (CHRS)Healthcare | Biotechnology | Redwood City, United States | NasdaqGM
1.47 USD
-0.07
(-4.545%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:07 a.m. EDT
The investment case here is fundamentally broken. The company has endured six consecutive years of negative annual returns, with the stock price collapsing nearly 96% over the last nine years. This is not a temporary setback; it is a structural implosion where the market has repeatedly rejected the business model. Despite a recent 27% share price rise mentioned in headlines, the underlying reality remains dire: negative operating cash flow, negative free cash flow, and a forward P/E that indicates no expected earnings. The balance sheet is fragile, and the lack of any dividend payout confirms the capital is being consumed by operations rather than returned to shareholders. While analysts see a path to recovery, the data shows a company that has failed to generate value for nearly a decade. The short-term outlook is murky at best, likely dragging along until the next clinical readout, but the long-term thesis is non-existent given the relentless multi-year decline. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.090476 |
| AutoETS | 0.128196 |
| AutoARIMA | 0.128199 |
| MSTL | 0.131370 |
| MSTL_115 | 0.152826 |
| MSTL_84 | 0.169969 |
| MSTL_84_115 | 0.211889 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 9.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.352 |
| Excess Kurtosis | -0.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 69.155 |
| Revenue per Share | 0.383 |
| Market Cap | 226,747,360 |
| Forward P/E | -1.44 |
| Beta | 0.98 |
| Profit Margins | 397.30% |
| Previous Name | Coherus BioSciences, Inc. |
| Website | https://www.coherus.com |
As of July 11, 2026, 6:07 a.m. EDT: Speculators are positioning for a continued decline, evidenced by heavy put open interest at strikes significantly above the current price (2.0 and 3.0) relative to call volume. While there is some call activity at the 3.0 strike, the overwhelming open interest concentration in out-of-the-money puts suggests a bearish sentiment expecting further downside before the next major catalyst.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.73144877 |
| Address1 | 333 Twin Dolphin Drive |
| Address2 | Suite 600 |
| All Time High | 38.1 |
| All Time Low | 0.66 |
| Ask | 1.9 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Daily Volume10 Day | 1,057,040 |
| Average Daily Volume3 Month | 1,166,868 |
| Average Volume | 1,166,868 |
| Average Volume10Days | 1,057,040 |
| Beta | 0.979 |
| Bid | 1.07 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.51 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.47 |
| Current Ratio | 1.557 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.5399 |
| Day Low | 1.46 |
| Debt To Equity | 69.155 |
| Display Name | Coherus BioSciences |
| Earnings Call Timestamp End | 1,778,533,200 |
| Earnings Call Timestamp Start | 1,778,533,200 |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -163,391,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.698 |
| Enterprise To Revenue | 2.433 |
| Enterprise Value | 114,071,352 |
| Eps Current Year | -0.745 |
| Eps Forward | -1.02 |
| Eps Trailing Twelve Months | -1.42 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.5607 |
| Fifty Day Average Change | -0.09070003 |
| Fifty Day Average Change Percent | -0.058114965 |
| Fifty Two Week Change Percent | 73.144875 |
| Fifty Two Week High | 2.616 |
| Fifty Two Week High Change | -1.1459999 |
| Fifty Two Week High Change Percent | -0.43807337 |
| Fifty Two Week Low | 0.81 |
| Fifty Two Week Low Change | 0.66 |
| Fifty Two Week Low Change Percent | 0.81481487 |
| Fifty Two Week Range | 0.81 - 2.616 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,415,284,200,000 |
| Float Shares | 132,526,887 |
| Forward Eps | -1.02 |
| Forward P E | -1.4411765 |
| Free Cashflow | -27,062,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 145 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.68059 |
| Gross Profits | 31,908,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.1866 |
| Held Percent Institutions | 0.38653 |
| Implied Shares Outstanding | 154,249,900 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California. |
| Long Name | Coherus Oncology, Inc. |
| Market | us_market |
| Market Cap | 226,747,360 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_206928583 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-14 |
| Net Income To Common | -172,660,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 226,747,353 |
| Number Of Analyst Opinions | 5 |
| Open | 1.5399 |
| Operating Cashflow | -170,572,992 |
| Operating Margins | -2.93672 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 649 3530 |
| Pre Market Change | 0.00999999 |
| Pre Market Change Percent | 0.68027145 |
| Pre Market Price | 1.48 |
| Pre Market Time | 1,784,024,345 |
| Prev Name | Coherus BioSciences, Inc. |
| Previous Close | 1.54 |
| Price Eps Current Year | -1.9731544 |
| Price Hint | 4 |
| Price To Book | 2.882353 |
| Price To Sales Trailing12 Months | 4.8364515 |
| Profit Margins | 3.9729998 |
| Quick Ratio | 1.432 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0699999 |
| Regular Market Change Percent | -4.54545 |
| Regular Market Day High | 1.5399 |
| Regular Market Day Low | 1.46 |
| Regular Market Day Range | 1.46 - 1.5399 |
| Regular Market Open | 1.5399 |
| Regular Market Previous Close | 1.54 |
| Regular Market Price | 1.47 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 550,252 |
| Return On Assets | -0.32796 |
| Revenue Growth | 0.62 |
| Revenue Per Share | 0.383 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 154,249,900 |
| Shares Percent Shares Out | 0.1684 |
| Shares Short | 25,975,163 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 27,872,603 |
| Short Name | Coherus Oncology, Inc. |
| Short Percent Of Float | 0.1735 |
| Short Ratio | 26.68 |
| Source Interval | 15 |
| State | CA |
| Symbol | CHRS |
| Target High Price | 12.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.8 |
| Target Median Price | 7.0 |
| Total Cash | 167,048,000 |
| Total Cash Per Share | 1.083 |
| Total Debt | 54,372,000 |
| Total Revenue | 46,883,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.42 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.615275 |
| Two Hundred Day Average Change | -0.145275 |
| Two Hundred Day Average Change Percent | -0.089938246 |
| Type Disp | Equity |
| Volume | 550,252 |
| Website | https://www.coherus.com |
| Zip | 94,065 |